The study examines the safety and effectiveness of two treatments, **TSC-100** and **TSC-101**, for patients with certain blood cancers: **AML** (Acute Myeloid Leukemia), **MDS** (Myelodysplastic Syndromes), and **ALL** (Acute Lymphoblastic Leukemia). Patients receive a stem cell transplant from a family member with a similar genetic makeup, known as a **haploidentical donor**. The main goal is to find out if TSC-100 and TSC-101 are safe and how well they work when given with the standard treatment. The study is open-label, meaning both the patients and doctors know which treatment is being given. **Key Points**: - Participants will receive up to two doses of TSC-100 or TSC-101 intravenously, along with standard care. - The study will last for 2 years with follow-ups to check for side effects and effectiveness. - Eligible participants must be at least 18 years old and not pregnant; they must also agree to long-term follow-up. This study could offer new treatment options for patients, but it's important to consider the time commitment and potential risks.